Chronic Obstructive Pulmonary DiseasePhase 2/3TMSNCT00951782
Deep High-Frequency Repetitive Transcranial Magnetic Stimulation for Smoking Cessation
A Phase 2/3 study testing High frequency TMS and Low frequency TMS in people with Chronic Obstructive Pulmonary Disease and Smoking, run by BeerYaakov Mental Health Center at 1 site in Israel.
Trial summary
Deep transcranial magnetic stimulation (TMS) is currently being evaluated as a treatment option in major depression. It has been shown to be a safe procedure . Deep transcranial magnetic stimulation coils are designed to maximize the electrical field deep in the brain by the summation of separate fields projected into… Read more about this study
- Who is it for?
- Ages 21 to 70 years
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease, Smoking
- What is being tested?
- High frequency TMS and Low frequency TMS
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 115 participants
- Where
- 1 siteIsrael
- Study dates
- Oct 2009to May 2013
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female patients, Aged 21-70 years.
- Subjects who smoke >20 cigarettes per day.
- Subjects are diagnosed as suffering from COPD
- Patients who are motivated to quit smoking.
- Patients who failed to respond to all 3 of the following anti-smoking treatments:
- po Bupropion (Zyban/Wellbutrin) or Varenicline (Champix)
- Nicotine patch/ nicotine gum
- CBT (Cognitive behavioral therapy)
Who cannot join
- History of a primary major psychiatric or cognitive disorder according to DSM IV.
- Current alcohol or other substance abuse or dependence.
- Alcohol or other substance abuse or dependence during the last 12 months before recruitment.
- History of or evidence of significant brain malformation or neoplasm, head injury, cerebral vascular events, neurodegenerative disorder affecting the brain or prior brain surgery.
- No neurological co-morbidity.
- No psychiatric co-morbidity.
Show all 15Show fewer
- No psychotropic medications.
- Severe somatic co morbidity.
- Cardiac pace makers, other electronic implants, intracranial metallic particles.
- History of seizures or epileptiform activity.
- Pregnancy and lactation.
- Patients who cannot communicate reliably with the investigator or who are not likely to cope with the requirements of the experiment.
- Patients unwilling or unable to give written informed consent.
- Patients with a high risk for severe violence or suicidality as assessed during the screening interview.
- Participation in a clinical trial within the last 30 days before the beginning of this clinical trial or similar participation in another clinical trial.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Deep High-Frequency Repetitive Transcranial Magnetic Stimulation for Smoking Cessation in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Deep transcranial magnetic stimulation (TMS) is currently being evaluated as a treatment option in major depression. It has been shown to be a safe procedure . Deep transcranial magnetic stimulation coils are designed to maximize the electrical field deep in the brain by the summation of separate fields projected into the skull from several points around its periphery. The device is planned to minimize the accumulation of electrical charge on the surface of the brain. Such accumulation can give rise to an electrostatic field that might reduce the magnitude of the induced electric field both at the surface and inside, thus reducing the depth penetration of the induced electric field . Deep transcranial magnetic stimulation could be more effective than repetitive transcranial magnetic stimulation due to its deeper penetration into brain tissues . The deeper penetration should produce greater action on nerve fibers connecting the prefrontal cortex to the limbic system.
The ability of high-frequency repetitive transcranial magnetic stimulation (rTMS) to alter dopaminergic neurotransmission in subcortical structures could explain recent reports, which suggest that it has the potential to reduce smoking and nicotine craving. Ecihhammer et al demonstrated a reduction in the number of cigarettes smoked and in the desire to smoke after a single rTMS treatment (Eichhammer et al., 2003). In addition, Johan et al in a cross-over, double-blind, placebo-controlled study demonstrated a reduction in cigarette consumption and desire to smoke after a single repetitive transcranial magnetic stimulation treatment (Johann et al., 2003). Recently, the investigators have finished a complete study on nicotine addiction using repetitive transcranial magnetic stimulation for 10 consecutive days. They have found that 10 days of rTMS reduced significantly better from placebo the number of cigarettes smoked, nicotine dependence and craving (Amiaz et al 2007, in preparation). Interestingly, some of the effects were stronger in the sub-group of patients that were presented with smoking-related pictures immediately prior to stimulation onset. Although, these results are interesting and exciting, they have two important caveats. First, only about 50%-60% of the smokers responded to the repetitive transcranial magnetic stimulation treatment. Second, among those responded to the treatment, only 10% had quit totally from smoking. Therefore, the potential therapeutic benefit of this treatment is limited. The investigators' hypothesis is that deep transcranial magnetic stimulation may be more efficient in smoking cessation due to it's deeper penetration and therefore it's capability to stimulate deeper fibers of the dopamine-reward-activating system.
Read the detailed description
Research Plan
- PARTICIPANTS Male and female cigarette smokers who suffer from COPD. From the general population aged 21-70 who wishes to quit smoking and failed to respond to previous anti-smoking treatment. They will be recruited by advertisements in the newspapers and specific websites. The number of participants in each sub-group (as described in the table below) will be 15-17. The investigators will recruit 90-102 subjects over two years.
II. SCREENING PROCEDURE
Before stimulation procedures onset, participants will undergo a clinical interview. All subject candidates will give written informed consent to take part in the study. Thereafter, they will be tested for their baseline pretreatment level of nicotine addiction in a screening meeting. This includes a report on the level of consumption (number of cigarettes smoked per day and overall duration in years) and a visual analog scale (VAS, see below for details). In addition, a urine sample for cotinine levels (nicotine metabolite) will be obtained in order to objectively measure levels of nicotine. In addition, several self-administered questionnaires will be given to the subjects in order to measure their baseline craving and nicotine dependence:
- Fagerstrom Test of Nicotine Dependence (FTND) (Heatherton et al., 1991). (Appendix no.1a)
- Tobacco Craving Questionnaire (TCQ) (Heishman et al., 2003). (Appendix no.1b)
- Full demographic questionnaire about medical condition and smoking habits. (Appendix no.1c)
III. MEASURES
All subjects will undergo various measurements on several visits, as described in table 1-3, for nicotine consumption, craving and dependence during the rTMS treatment visits:
- VAS: Visual Analogue Scale, on which the subject marks his/her subjective craving on a 10-cm-long scale in response to the following question: "How much do you crave a joint/bong right now?" This "desire to smoke rating" has been shown to be sensitive to assess self-reported levels of craving in nicotine smoking (Schuh and Stitzer, 1995; King and Meyer, 2000).
- Short TCQ: Tobacco Craving Questionnaire, the short version of the TCQ, which has 12 questions that can be divided into four categories: emotionality, expectancy, compulsivity and purposefulness.
- FTND: Fagerstrom Test of Nicotine Dependence. Measures the level of nicotine dependence (Dijkstra and Tromp, 2002).
- Self-report of the number of cigarettes smoked on the previous day.
- Urine sample.
- BR: desire to smoke and effect on hunger.
- Spatial span memory test - in order to evaluate the effect of deep rTMS on spatial memory. This test will be conducted in the screening interview and after 10 days of rTMS treatment.
IV. PRESENTATION OF PHOTOGRAPHS
It has recently been demonstrated that in nicotine-deprived smokers, reward and attention circuits are reactivated by mere exposure to smoking-related images, in contrast with neutral images (Due et al., 2002). In our experiment, prior to stimulation onset 14 'neutral' or 'nicotine-related' colored photographs will be presented on a computer screen to the participants while there are seated. The 'nicotine-related' photographs will be composed from smoking-related scenes, such as lighting up a cigarette, smoking puffs etc. 'Neutral' photos will consist of matched pictures without any nicotine related content (e.g. inanimate objects, hands, faces etc.). As the investigators have previously shown with the figure-8 coil experiment, there was a stronger effect of the rTMS treatment in subjects exposed to the nicotine photographs. The investigators propose that presentation of the nicotine photographs causes the nicotine-related memories to become activated and therefore, labile for interference, as previously has been shown (Dudai, 2004 ).
- EXPERIMENTAL PROCEDURES
After screening of the participants while taking into account the inclusion and exclusion criteria (described above), they will be divided into experimental groups having similar levels of nicotine addiction and demographic background. At selected time afterwards, participants will be introduced to the TMS treatment protocol. They will be asked to refrain from smoking nicotine for two hours prior to attending the daily treatment session. Prior to stimulation onset, the participants will be presented with 'nicotine' photographs. Immediately after the offset of the photographs presentation (while memory is reactivated) the participants will be applied with real or sham rTMS stimulation. The stimulation site will be the PFC using the H-ADD coil.
Time Table:
There will be daily treatments for two weeks accompanied with assessment of the level of nicotine addiction on selected days using the above-mentioned tools. Thereafter, subjects will continue to have maintenance rTMS/sham stimulation treatment: 3 times a week for one week, two times a week in the forth and fifth week, once a week in the sixth and seventh week (see also table 2). After maintenance, participants will continue with follow up visits that will occur once a month for six months (see table 3). This protocol will allow evaluation of the short and long-term effects of the rTMS treatment with the possible fluctuations over time.
TMS procedure:
The investigators will use a Magstim Super Rapid stimulator, which produces a biphasic pulse, and our special customized equipment and coils for deep brain stimulation (Zangen, 2005 ). The TMS coils, which will be used in this study will be specific versions of the H-coil, depending on the region of stimulation. The H-coil versions used in this study, the H-ADD coil, have been tested in healthy volunteers and found to be safe and to induce some short-lasting (1 hour) cognitive alterations (Levkovitz et al., 2007, accepted). The theoretical considerations and design principles of the H-coils are explained in a previous study (Roth, 2002 ). In short, the H-ADD coil is designed to generate summation of the electric field in a specific brain region by locating coil elements at different locations around this region, all of which have a common current component which induce electric field in the desired direction .In addition, since a radial component has a dramatic effect on electric field magnitude and on the rate of decay of the electric field with distance, the overall length of coil elements which are nontangential to the skull should be minimized, and these elements as well as coil elements having current component in the opposite direction should be located as distant as possible from the brain region to be activated.
The H-ADD coil is placed on the scalp over the left motor cortex. The center of the coil is placed on the scalp with the handle pointing backward and laterally at a 45° angle away from the midline. Thus the current induced in the neural tissue is directed approximately perpendicular to the line of the central sulcus and therefore optimal for activating the corticospinal pathways transsynaptically (Kaneko et al., 1996). With a slightly suprathreshold stimulus intensity, the stimulating H-ADD coil is moved over the left hemisphere to determine the optimal position for eliciting MEPs of maximal amplitudes (the 'hot spot'). The optimal position of the coil is then marked relative to the 'hot spot' to ensure coil placement throughout the experiment. Resting motor threshold is determined to the nearest 1% of the maximum stimulator output and is defined as the minimal stimulus intensity required to produce MEPs of >50 µV in ≥5 of 10 consecutive trials at least 5 sec apart. The H-ADD coil is held in a stable coil holder ,which can be adjusted at different points relative to the 'hot spot' on the scalp.
Stimulation Protocols:
The investigators will use either sham or real H-ADD coils, which both produce similar noise and share a similar shape (as the investigators have been using in our study on healthy volunteers). Stimulation intensity will be 120% relative to the motor threshold in the 'hot spot'. PFC location will be determined as follows: 6 cm anterior to the motor 'hot spot' and symmetric.
High frequency stimulation will by applied in order to achieve activation of the stimulated brain area and possibly induce LTP like plasticity. The stimulation protocol will be 33 trains of 10 Hz for 3 seconds, ITI of 20 seconds. The total treatment duration will be 759 seconds with 990 pulses. . For that purpose the investigators have designed a special cooling system for our coils and used them successfully in our healthy volunteers study (Levkovitz et al., 2007, accepted).
- Conditions
- Chronic Obstructive Pulmonary Disease, Smoking
- Being tested
- High frequency TMS, Sham TMS, Low frequency TMS
- Keywords
- COPD
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Smoking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High frequency TMSDevice
deep TMS HADD coil
Sham TMSDevice
sham deep TMS HADD coil
Low frequency TMSDevice
Deep TMS - HADD coil
| Study group | Role | What they receive |
|---|---|---|
| High frequency TMS + smoking cue | Active comparator | Not described Receives: Device: High frequency TMS |
| Sham TMS + smoking cue | Sham comparator | Not described Receives: Device: Sham TMS |
| Low frequency TMS +smoking cue | Active comparator | Not described Receives: Device: Low frequency TMS |
| Sham TMS - no cue | Sham comparator | Not described Receives: Device: Sham TMS |
| High frequency TMS - no cue | Active comparator | Not described Receives: Device: High frequency TMS |
| Low frequency - no cue | Active comparator | Not described Receives: Device: Low frequency TMS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Nicotine consumption(number of cigarets per day and cotinine levels )and craving (questionaires)at end of treatment (3rd week)
Measured: 3 weeks of treatment (and additional 34 weeks of maintenance & follow-up)
Secondary outcomes (1)
Nicotine consumption(number of cigarets per day and cotinine levels )and craving (questionaires)at end of maintenance & follow-up(37th week)
Measured: 37 weeks (follow up)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Aug 2009 (estimated)
- Study startOct 2009
- Primary completionNov 2012
- Study completionMay 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic Obstructive Pulmonary DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 115 participants (actual)
Sponsor and investigators
- Lead sponsor
- BeerYaakov Mental Health Center
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Pinhas Dannon, BeerYaakov Mental Health Center
- Investigators
- Oded Rosenberg, M.D., Study director, Beer Yaakov MHILimor Dinur Klein, Study director, Beer Yaakov MHI
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00951782
- Sponsor's protocol ID
- 234-CTIL
- Acronym
- TMS
- Status last verified
- Dec 2013
- First submitted
- 14 Jul 2009
- Last updated
- 20 Dec 2013
- Results posted
- No
- Data monitoring committee
- No
Publications
Dinur-Klein L, Dannon P, Hadar A, Rosenberg O, Roth Y, Kotler M, Zangen A. Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial. Biol Psychiatry. 2014 Nov 1;76(9):742-9. doi: 10.1016/j.biopsych.2014.05.020. Epub 2014 Jun 5.
PubMed 25038985
Study at a glance
From the registry record, last updated by the sponsor on 20 Dec 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Deep High-Frequency Repetitive Transcranial Magnetic Stimulation for Smoking Cessation in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- ClinicalTrials.gov ID
- NCT00951782
- Acronym / sponsor ID
- TMS / 234-CTIL
- Conditions
- Chronic Obstructive Pulmonary Disease, Smoking
- Keywords
- COPD
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 115 participants (actual)
- Lead sponsor
- BeerYaakov Mental Health CenterOther government
- Study start
- Oct 2009
- Primary completion
- Nov 2012 (actual)
- Study completion
- May 2013 (actual)
- First posted
- 4 Aug 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Deep transcranial magnetic stimulation (TMS) is currently being evaluated as a treatment option in major depression. It has been shown to be a safe procedure . Deep transcranial magnetic stimulation coils are designed to maximize the electrical field deep in the brain by the summation of separate fields projected into the skull from several points around its periphery. The device is planned to minimize the accumulation of electrical charge on the surface of the brain. Such accumulation can give rise to an electrostatic field that might reduce the magnitude of the induced electric field both at the surface and inside, thus reducing the depth penetration of the induced electric field . Deep transcranial magnetic stimulation could be more effective than repetitive transcranial magnetic stimulation due to its deeper penetration into brain tissues . The deeper penetration should produce greater action on nerve fibers connecting the prefrontal cortex to the limbic system.
The ability of high-frequency repetitive transcranial magnetic stimulation (rTMS) to alter dopaminergic neurotransmission in subcortical structures could explain recent reports, which suggest that it has the potential to reduce smoking and nicotine craving. Ecihhammer et al demonstrated a reduction in the number of cigarettes smoked and in the desire to smoke after a single rTMS treatment (Eichhammer et al., 2003). In addition, Johan et al in a cross-over, double-blind, placebo-controlled study demonstrated a reduction in cigarette consumption and desire to smoke after a single repetitive transcranial magnetic stimulation treatment (Johann et al., 2003). Recently, the investigators have finished a complete study on nicotine addiction using repetitive transcranial magnetic stimulation for 10 consecutive days. They have found that 10 days of rTMS reduced significantly better from placebo the number of cigarettes smoked, nicotine dependence and craving (Amiaz et al 2007, in preparation). Interestingly, some of the effects were stronger in the sub-group of patients that were presented with smoking-related pictures immediately prior to stimulation onset. Although, these results are interesting and exciting, they have two important caveats. First, only about 50%-60% of the smokers responded to the repetitive transcranial magnetic stimulation treatment. Second, among those responded to the treatment, only 10% had quit totally from smoking. Therefore, the potential therapeutic benefit of this treatment is limited. The investigators' hypothesis is that deep transcranial magnetic stimulation may be more efficient in smoking cessation due to it's deeper penetration and therefore it's capability to stimulate deeper fibers of the dopamine-reward-activating system.
Detailed description
Research Plan
- PARTICIPANTS Male and female cigarette smokers who suffer from COPD. From the general population aged 21-70 who wishes to quit smoking and failed to respond to previous anti-smoking treatment. They will be recruited by advertisements in the newspapers and specific websites. The number of participants in each sub-group (as described in the table below) will be 15-17. The investigators will recruit 90-102 subjects over two years.
II. SCREENING PROCEDURE
Before stimulation procedures onset, participants will undergo a clinical interview. All subject candidates will give written informed consent to take part in the study. Thereafter, they will be tested for their baseline pretreatment level of nicotine addiction in a screening meeting. This includes a report on the level of consumption (number of cigarettes smoked per day and overall duration in years) and a visual analog scale (VAS, see below for details). In addition, a urine sample for cotinine levels (nicotine metabolite) will be obtained in order to objectively measure levels of nicotine. In addition, several self-administered questionnaires will be given to the subjects in order to measure their baseline craving and nicotine dependence:
- Fagerstrom Test of Nicotine Dependence (FTND) (Heatherton et al., 1991). (Appendix no.1a)
- Tobacco Craving Questionnaire (TCQ) (Heishman et al., 2003). (Appendix no.1b)
- Full demographic questionnaire about medical condition and smoking habits. (Appendix no.1c)
III. MEASURES
All subjects will undergo various measurements on several visits, as described in table 1-3, for nicotine consumption, craving and dependence during the rTMS treatment visits:
- VAS: Visual Analogue Scale, on which the subject marks his/her subjective craving on a 10-cm-long scale in response to the following question: "How much do you crave a joint/bong right now?" This "desire to smoke rating" has been shown to be sensitive to assess self-reported levels of craving in nicotine smoking (Schuh and Stitzer, 1995; King and Meyer, 2000).
- Short TCQ: Tobacco Craving Questionnaire, the short version of the TCQ, which has 12 questions that can be divided into four categories: emotionality, expectancy, compulsivity and purposefulness.
- FTND: Fagerstrom Test of Nicotine Dependence. Measures the level of nicotine dependence (Dijkstra and Tromp, 2002).
- Self-report of the number of cigarettes smoked on the previous day.
- Urine sample.
- BR: desire to smoke and effect on hunger.
- Spatial span memory test - in order to evaluate the effect of deep rTMS on spatial memory. This test will be conducted in the screening interview and after 10 days of rTMS treatment.
IV. PRESENTATION OF PHOTOGRAPHS
It has recently been demonstrated that in nicotine-deprived smokers, reward and attention circuits are reactivated by mere exposure to smoking-related images, in contrast with neutral images (Due et al., 2002). In our experiment, prior to stimulation onset 14 'neutral' or 'nicotine-related' colored photographs will be presented on a computer screen to the participants while there are seated. The 'nicotine-related' photographs will be composed from smoking-related scenes, such as lighting up a cigarette, smoking puffs etc. 'Neutral' photos will consist of matched pictures without any nicotine related content (e.g. inanimate objects, hands, faces etc.). As the investigators have previously shown with the figure-8 coil experiment, there was a stronger effect of the rTMS treatment in subjects exposed to the nicotine photographs. The investigators propose that presentation of the nicotine photographs causes the nicotine-related memories to become activated and therefore, labile for interference, as previously has been shown (Dudai, 2004 ).
- EXPERIMENTAL PROCEDURES
After screening of the participants while taking into account the inclusion and exclusion criteria (described above), they will be divided into experimental groups having similar levels of nicotine addiction and demographic background. At selected time afterwards, participants will be introduced to the TMS treatment protocol. They will be asked to refrain from smoking nicotine for two hours prior to attending the daily treatment session. Prior to stimulation onset, the participants will be presented with 'nicotine' photographs. Immediately after the offset of the photographs presentation (while memory is reactivated) the participants will be applied with real or sham rTMS stimulation. The stimulation site will be the PFC using the H-ADD coil.
Time Table:
There will be daily treatments for two weeks accompanied with assessment of the level of nicotine addiction on selected days using the above-mentioned tools. Thereafter, subjects will continue to have maintenance rTMS/sham stimulation treatment: 3 times a week for one week, two times a week in the forth and fifth week, once a week in the sixth and seventh week (see also table 2). After maintenance, participants will continue with follow up visits that will occur once a month for six months (see table 3). This protocol will allow evaluation of the short and long-term effects of the rTMS treatment with the possible fluctuations over time.
TMS procedure:
The investigators will use a Magstim Super Rapid stimulator, which produces a biphasic pulse, and our special customized equipment and coils for deep brain stimulation (Zangen, 2005 ). The TMS coils, which will be used in this study will be specific versions of the H-coil, depending on the region of stimulation. The H-coil versions used in this study, the H-ADD coil, have been tested in healthy volunteers and found to be safe and to induce some short-lasting (1 hour) cognitive alterations (Levkovitz et al., 2007, accepted). The theoretical considerations and design principles of the H-coils are explained in a previous study (Roth, 2002 ). In short, the H-ADD coil is designed to generate summation of the electric field in a specific brain region by locating coil elements at different locations around this region, all of which have a common current component which induce electric field in the desired direction .In addition, since a radial component has a dramatic effect on electric field magnitude and on the rate of decay of the electric field with distance, the overall length of coil elements which are nontangential to the skull should be minimized, and these elements as well as coil elements having current component in the opposite direction should be located as distant as possible from the brain region to be activated.
The H-ADD coil is placed on the scalp over the left motor cortex. The center of the coil is placed on the scalp with the handle pointing backward and laterally at a 45° angle away from the midline. Thus the current induced in the neural tissue is directed approximately perpendicular to the line of the central sulcus and therefore optimal for activating the corticospinal pathways transsynaptically (Kaneko et al., 1996). With a slightly suprathreshold stimulus intensity, the stimulating H-ADD coil is moved over the left hemisphere to determine the optimal position for eliciting MEPs of maximal amplitudes (the 'hot spot'). The optimal position of the coil is then marked relative to the 'hot spot' to ensure coil placement throughout the experiment. Resting motor threshold is determined to the nearest 1% of the maximum stimulator output and is defined as the minimal stimulus intensity required to produce MEPs of >50 µV in ≥5 of 10 consecutive trials at least 5 sec apart. The H-ADD coil is held in a stable coil holder ,which can be adjusted at different points relative to the 'hot spot' on the scalp.
Stimulation Protocols:
The investigators will use either sham or real H-ADD coils, which both produce similar noise and share a similar shape (as the investigators have been using in our study on healthy volunteers). Stimulation intensity will be 120% relative to the motor threshold in the 'hot spot'. PFC location will be determined as follows: 6 cm anterior to the motor 'hot spot' and symmetric.
High frequency stimulation will by applied in order to achieve activation of the stimulated brain area and possibly induce LTP like plasticity. The stimulation protocol will be 33 trains of 10 Hz for 3 seconds, ITI of 20 seconds. The total treatment duration will be 759 seconds with 990 pulses. . For that purpose the investigators have designed a special cooling system for our coils and used them successfully in our healthy volunteers study (Levkovitz et al., 2007, accepted).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| High frequency TMS + smoking cue | Active comparator | Device: High frequency TMS |
| Sham TMS + smoking cue | Sham comparator | Device: Sham TMS |
| Low frequency TMS +smoking cue | Active comparator | Device: Low frequency TMS |
| Sham TMS - no cue | Sham comparator | Device: Sham TMS |
| High frequency TMS - no cue | Active comparator | Device: High frequency TMS |
| Low frequency - no cue | Active comparator | Device: Low frequency TMS |
Who may qualify
- Ages
- 21 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Male or female patients, Aged 21-70 years.
- Subjects who smoke >20 cigarettes per day.
- Subjects are diagnosed as suffering from COPD
- Patients who are motivated to quit smoking.
- Patients who failed to respond to all 3 of the following anti-smoking treatments:
Key exclusion criteria (15 listed)
- History of a primary major psychiatric or cognitive disorder according to DSM IV.
- Current alcohol or other substance abuse or dependence.
- Alcohol or other substance abuse or dependence during the last 12 months before recruitment.
- History of or evidence of significant brain malformation or neoplasm, head injury, cerebral vascular events, neurodegenerative disorder affecting the brain or prior brain surgery.
- No neurological co-morbidity.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High frequency TMSdeep TMS HADD coil | Device | High frequency TMS + smoking cue, High frequency TMS - no cue |
| Sham TMSsham deep TMS HADD coil | Device | Sham TMS + smoking cue, Sham TMS - no cue |
| Low frequency TMSDeep TMS - HADD coil | Device | Low frequency - no cue, Low frequency TMS +smoking cue |
Primary outcome
Nicotine consumption(number of cigarets per day and cotinine levels )and craving (questionaires)at end of treatment (3rd week)
Time frame: 3 weeks of treatment (and additional 34 weeks of maintenance & follow-up)
1 secondary outcome
Nicotine consumption(number of cigarets per day and cotinine levels )and craving (questionaires)at end of maintenance & follow-up(37th week)
Time frame: 37 weeks (follow up)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Dec 2013.
- Derived from this study: PubMed 25038985Dinur-Klein L, Dannon P, Hadar A, Rosenberg O, Roth Y, Kotler M, Zangen A. Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial. Biol Psychiatry. 2014 Nov 1;76(9):742-9. doi: 10.1016/j.biopsych.2014.05.020. Epub 2014 Jun 5.
Related trials for Chronic Obstructive Pulmonary Disease
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Oded Rosenberg, M.D. study director
Beer Yaakov MHI
Limor Dinur Klein study director
Beer Yaakov MHI
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing High frequency TMS and Low frequency TMS in people with Chronic Obstructive Pulmonary Disease and Smoking, run by BeerYaakov Mental Health Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Dec 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Nicotine consumption(number of cigarets per day and cotinine levels )and craving (questionaires)at end of treatment (3rd week) (time frame: 3 weeks of treatment (and additional 34 weeks of maintenance & follow-up)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00951782, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2013.